Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction TPX in High Risk NPC
NCT02786641Phase 3Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2016
- Primary completion
- Aug 2018
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, cisplatin, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
docetaxelcisplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT02786641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02786641.